IVIG (Immunoglobulin) as an Adjuvant Therapy in COVID-19
Keywords:
Covid-19, coronavirus, Immunoglobulin, lymphocytopenia, pneumoniaAbstract
COVID-19 viral disease appeared in China in December 2019 and then spread around the world, affecting millions and causing the death of thousands of people. Its danger in simple and easy infection transmission methods. Some believe that it has moved from the bat to the human and its symptoms are high temperature, dry cough and difficulty breathing, and symptoms vary from person to person, as they may not appear on some and be severe in others. Laboratory, in COVID-19 the rate of D-dimer increase so we recommended using of Enoxaparin sodium to raise the level of liquidity in the blood, thereby reducing the chance of thrombosis and reducing the value of D-dimer. In COVID-19 also we find the PO2 decrease in arterial blood gas analysis, increase liver enzyme levels, increase ferritin value and decrease the No of lymphocyte. Low percentage of lymphocytes is one of the predictions for infection with COVID-19 virus. Lymphocytes originate from the bone marrow and include B cells, T cells, and natural killer cells. COVID-19 binds to lymphocyte receptors and destroys them. In this case, we recommend using immunoglobulin to maintain these cells as an adjuvant therapy in COVID-19.
References
. Chen, N. Epidemiological and clinical characteristics of 99 cases of COVID-19, China: 2020.
. World Health Organization. W. H. O. model list of essential medicines, Geneva: World Health Organization, 2019.
. Wang, D. et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia, Wuhan, China: 2020, JAMA 323, 1061–1069.
. Novel Coronavirus 2019 infection in Wuhan, China, Outbreak update, Canada: 21-1-2020.
. Huang C, Wang Y, Li X, et al. Clinical features of COVID-19 patients in (Wuhan, China), Lancet: 2020.
. Lu R, Zhao X, Li J et al. Genomic characterization & epidemiology of novel coronavirus 2019, implications for virus origins and receptor engaged: 2020.
. Fischer. Inhibitory vigor of tumor cell derived lactic acid on T lymphocytes of human, Study of blood: 2007.Han, Xiaoyu; Cao, Yukun; Jiang, Nanchuan; Chen, Yan; Alwalid, Osamah; Zhang, Xin; Gu, Jin; Dai, Meng; Liu, Jie; Zhu, Wanyue; Zheng, Chuansheng. Novel Coronavirus 2019 Progression Course in seventeen Discharged Patients, Comparison of Clinical and Thin-Section CT faces during Recovery, Clinical Infectious Diseases: 2020.
. Centers of Disease Control & Prevention, Coronavirus Disease 2019 (COVID-19), the original on 4 March 2020.
. Merriam-Webster Dictionary. B cell, Encyclopedia Britannica, Retrieved 28 October2011.
. Janeway, Charles; Travers, Paul; Walport, Mark; Shlomchik, Mark. Immunobiology (5th Ed), New York and London, Garland Science: 2001 ISBN 0-8153-4101-6.
. Abbas, A. K.; Lichtman, A. H. Cellular and Molecular Immunology (5th Ed.), Saunders, Philadelphia, 2003 ISBN 0-7216-0008-5.
. Berrington, J. E.; Barge, D.; Fenton, A. C.; Cant, A. J.; Spickett, G. P. Lymphocyte subsets in significantly preterm UK infants in the first year of life analyzed by single platform flow cytometery, Clinical and Experimental Immunology: (May 2005), 140(2): 289–92. Doi: 10.1111/j.1365-2249.2005.02767.x. PMC 1809375. PMID 15807853.
. The American Society of Health-System Pharmacists. Immunoglobulin, Archived from the original on 9 January 2017. Retrieved 8 January 2017.
. Www.blood.gov.au. Access to Subcutaneous Immunoglobulin (SCIg) | National Blood Authority, Retrieved 14 November 2019.
. Www.blood.gov.au. Criteria for the Clinical Use of Intravenous Immunoglobulin in Australia | National Blood Authority, Retrieved 14 November 2019.
Downloads
Published
How to Cite
Issue
Section
License
Authors who submit papers with this journal agree to the following terms.
